AI-ROL: Artificial Intelligence in Breast Cancer Screening in Region Östergötland Linkoping

Sponsor
Ostergotland County Council, Sweden (Other)
Overall Status
Completed
CT.gov ID
NCT05048095
Collaborator
(none)
15,500
1
4
3835.6

Study Details

Study Description

Brief Summary

The purpose of this observational study is to assess whether the use of AI (Transpara®) can lead to an improved quality of a double reading mammography screening program. This is investigated by performing AI as a third reader and as a decision support during the consensus meeting, compared with conventional mammography screening (double reading and consensus without AI).

Condition or Disease Intervention/Treatment Phase
  • Other: AI cancer detection system

Detailed Description

The AI cancer detection system will act as a 3rd reader and will recall additional cases to the consensus conference: the exams that were not recalled by double reading but are classified as the 3% most suspicious exams, based on AI derived cancer-risk scores. Secondly, AI is used as a decision support during consensus. AI risk scores and Computer-Aided Detection (CAD)-marks of suspicious calcifications and soft tissue lesions are provided to the reader(s).

The hypothesis of this study is that the use of AI has the potential to improve the quality of the screening program by increasing the cancer detection rate without affecting the recall rate.

Study Design

Study Type:
Observational
Actual Enrollment :
15500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Use of AI as a Third Reader and During Consensus in a Double Reading Breast Cancer Screening Program in Sweden
Actual Study Start Date :
Oct 15, 2021
Actual Primary Completion Date :
Feb 15, 2022
Actual Study Completion Date :
Feb 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Screened women in Region Östergötland Linkoping

Other: AI cancer detection system
The use of AI as a third reader and as a decision support system during consensus meeting

Outcome Measures

Primary Outcome Measures

  1. Cancer Detection rate [After 4 months of inclusion]

    Proportion of women diagnosed with breast cancer among those recalled after consensus

  2. Recall or referral rate [After 4 months of inclusion]

    Proportion of women who are referred for further diagnostic workup after consensus

  3. Positive predictive value of referrals [After 4 months of inclusion]

    Proportion of women diagnosed with breast cancer among those referred

Secondary Outcome Measures

  1. Positive predictive value of Transpara® scores [After 4 months of inclusion]

    Proportion of breast cancers diagnosed among women with a given AI score

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 74 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women participating in the regular Breast Cancer Screening Program in Region Östergötland Linkoping
Exclusion Criteria:
  • Women with breast implants or other foreign implants in the mammogram

  • Women with symptoms or signs of suspected breast cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Region Östergötland Linköping Östergötland Sweden 58185

Sponsors and Collaborators

  • Ostergotland County Council, Sweden

Investigators

  • Principal Investigator: Håkan Gustafsson, PhD, Linköping University - University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Håkan Gustafsson, Adjunct Senior Lecturer, Ostergotland County Council, Sweden
ClinicalTrials.gov Identifier:
NCT05048095
Other Study ID Numbers:
  • NCT20210157-AI-ROL
First Posted:
Sep 17, 2021
Last Update Posted:
Apr 20, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Håkan Gustafsson, Adjunct Senior Lecturer, Ostergotland County Council, Sweden
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2022